Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $2.3 million.

  • Cue Biopharma's Accounts Payables fell 6373.19% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 6373.19%. This contributed to the annual value of $2.8 million for FY2024, which is 1936.59% down from last year.
  • As of Q3 2025, Cue Biopharma's Accounts Payables stood at $2.3 million, which was down 6373.19% from $3.6 million recorded in Q2 2025.
  • Cue Biopharma's 5-year Accounts Payables high stood at $6.5 million for Q3 2024, and its period low was $1.6 million during Q2 2022.
  • For the 5-year period, Cue Biopharma's Accounts Payables averaged around $3.0 million, with its median value being $2.6 million (2022).
  • As far as peak fluctuations go, Cue Biopharma's Accounts Payables skyrocketed by 16104.84% in 2024, and later crashed by 6373.19% in 2025.
  • Cue Biopharma's Accounts Payables (Quarter) stood at $2.6 million in 2021, then increased by 5.42% to $2.7 million in 2022, then grew by 28.19% to $3.5 million in 2023, then dropped by 19.37% to $2.8 million in 2024, then decreased by 16.83% to $2.3 million in 2025.
  • Its Accounts Payables was $2.3 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.8 million in Q1 2025.